July 5, 2024 — Lantheus Holdings, Inc., a main radiopharmaceutical-focused firm dedicated to enabling clinicians to Discover, Battle and Observe illness to ship higher affected person outcomes, at this time introduced its acquisition of the worldwide rights of Life Molecular Imaging’s RM2, focusing on the gastrin-releasing peptide receptor (GRPR), together with the related novel, clinical-stage radiotherapeutic and radiodiagnostic pair, known as 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2. This acquisition strengthens Lantheus’ presence in prostate most cancers and expands its pipeline to incorporate breast and different cancers. The settlement contains international rights to this radiotheranostic pair for an upfront fee of $35 million and potential regulatory milestone funds plus royalties.
Lantheus’ acquisition of worldwide rights to 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 underscores its dedication to pioneering most cancers care and marks a major step in the direction of addressing unmet medical wants in prostate and breast most cancers therapy. RM2 was found on the Universities Bern and Basel and growth was initially carried out by Bayer Pharma AG. It was subsequently licensed to Life Molecular. 68Ga-DOTA-RM2 targets cancers overexpressing GRPR, equivalent to prostate, breast, lung, pancreatic, colorectal, gastric and ovarian cancers and has been extensively studied in varied tumor sorts. First-in-human dosimetry confirmed a good security and dosimetry profile and confirmed preclinical information demonstrating dose-dependent efficacy of 177Lu-DOTA-RM2. Lantheus intends to start a Part 1/2a research with 177Lu-DOTA-RM2 in prostate most cancers sufferers in 2025. 68Ga-DOTA-RM2 will probably be used as a companion diagnostic.
“Whereas new PSMA-targeted diagnostics and therapeutics are remodeling prostate most cancers care, there are lots of sufferers for whom PSMA-targeted remedy might not be acceptable,” mentioned Brian Markison, Lantheus CEO. “Concentrating on GRPR with 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 creates a possible new choice to develop entry to radiotheranostics for extra prostate most cancers sufferers. This expands our therapeutic choices and opens avenues for business synergies.”
Life Molecular, a subsidiary of Life Healthcare Group, will full the Part 1/2a dose escalation research in collaboration with Lantheus.
“With Lantheus’ expertise creating and offering entry to radiotheranostics in most cancers, we’re assured in our resolution handy them the reins for this promising theranostic pair and are honored to work with them towards bettering the longer term for individuals with prostate and breast most cancers,” mentioned Ludger Dinkelborg, CEO, Life Molecular Imaging.
For extra data: www.lantheus.com
